IQV | NYSE
Next Earnings: Jul 27, 2026
Company Overview:
10 Year IQV Performance Metrics:
Unlock All Reports & Research Dividend Stocks.
[lev_ptables no_sale]IQV Earnings, Revenue, Cash & Debt, Shares Outstaning:
Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:
Ratios, Profit Margins & Return on Capital:
Projected Future Returns & Dividends for IQV
Based on past 10-year performance, here are IQV growth metrics:
Share price CAGR of +10.88%
Dividend CAGR of +0%
Using IQV CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:
| IQV (DRIP) | IQV - No DRIP | |
|---|---|---|
| Current Price | $208.05 | $208.05 |
| Start Shares | 48.07 | 48.07 |
| Start Value | $10,000 | $10,000 |
| After 10 years: | ||
| Final Share Count | 48.07 | 48.07 |
| Dividends Payment | $0.00 | $0.00 |
| Annual Dividends | $0 | $0 |
| Yield on cost | 0.00% | 0.00% |
| Share Price | $584.30 | $208.05 |
| Total Dividends | $0 | $0 |
| Final Value | $28,085 | $10,000 |
NOTE: Above numbers are our estimate based on IQV's Dividend and Price CAGR over past 10 years.
These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.
We cannot guarantee that your actual returns will meet these estimates.
Get the best Dividend Stock Research Tools:
[lev_ptables no_sale]Company Info
IQVIA Holdings Inc. (IQV) had its IPO on 2013-05-09, and is trader on NYSE stock exchange.
IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific. The company's operations are structured into three key divisions: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides a suite of cloud-native applications, complete with implementation services, and offers real-world data solutions designed to empower life sciences and healthcare providers in generating and disseminating evidence crucial for informed decision-making and improving patient outcomes. This division also delivers strategic and operational consulting, including advanced analytics support and outsourcing of commercial processes. Furthermore, it supplies country-level performance metrics detailing pharmaceutical sales, prescribing trends, medical treatments, and promotional activities across diverse channels like retail, hospital, and mail order, with data granularity extending to regional, postal code, and individual prescriber levels. Focusing on clinical trials, the Research & Development Solutions segment offers project management, clinical monitoring, broader clinical trial support, virtual trial capabilities, and strategic planning and design services. It also manages an extensive network of laboratory services, encompassing central, genomic, bioanalytical, ADME, discovery, vaccine, and biomarker analyses. The Contract Sales & Medical Solutions segment is responsible for engaging healthcare professionals and patients, alongside providing scientific strategy and medical affairs support. IQVIA's diverse clientele includes pharmaceutical, biotechnology, medical device and diagnostic, and consumer health companies. The company maintains a strategic collaboration with HealthCore, Inc. Founded in 1982, the firm was formerly known as Quintiles IMS Holdings, Inc. before rebranding as IQVIA Holdings Inc. in November 2017. Its headquarters are located in Durham, North Carolina.
IQV website: https://www.iqvia.com
